A Prospective Analysis of Early Discharge After Transfemoral Transcatheter Aortic Valve Implantation.

As transcatheter aortic valve implantation (TAVI) becomes more routinely used, the recommended duration of monitoring after uncomplicated TAVI remains indeterminate. Retrospective analysis suggests that discharge within 72 hours is safe, but prospective data are largely lacking. We therefore prospectively assess the feasibility and safety of early discharge (within 72 hours) after transfemoral TAVI using Edwards SAPIEN-XT and SAPIEN-3 prostheses.

Trends over the past 4 years in population characteristics, 30-day outcomes and 1-year survival in patients treated with transcatheter aortic valve implantation.

Background: Transcatheter aortic valve implantation (TAVI) is recommended in patients with severe aortic stenosis that is either inoperable or at high-risk for surgical valve replacement.

Aims: To evaluate trends in the feasibility and safety of transfemoral TAVI over the past 4 years.

Methods: Between 2010 and 2013, all consecutive patients undergoing TAVI in our institution were included in a prospective registry.